{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-21-000015","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2021-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.826217+00:00","generated_at":"2026-06-28T22:34:48.441544+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Skye Bioscience appoints Kaitlyn Arsenault as CFO, replacing interim Principal Accounting Officer","bullets":["Punit Dhillon resigned as interim Principal Accounting Officer effective Oct 4, 2021; Kaitlyn Arsenault appointed CFO immediately.","Arsenault receives options for 1.6M shares at $0.09; 10% vest immediately, remainder over 4 years semi-annually.","Annual base salary $300k with discretionary bonus up to 35% of base; severance of 6 months' salary if terminated not for cause.","Arsenault has 14+ years experience in life science accounting, previously consultant to Skye for 6 years and Assurance Manager at Friedman LLP.","Skye is a biopharma developing cannabinoid-derived molecules for unmet medical needs; CFO appointment supports clinical program advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-21-000015","json":"https://secwatch.observer/filing/0001516551-21-000015.json","markdown":"https://secwatch.observer/filing/0001516551-21-000015.md","text":"https://secwatch.observer/filing/0001516551-21-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655121000015/0001516551-21-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655121000015/skye-20211005.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T22:34:48.441544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c31631f54","claim":"Punit Dhillon resigned as interim Principal Accounting Officer at Skye Bioscience, Inc..","evidence_excerpt":"As of October 4, 2021, Punit Dhillon has tendered his resignation from his position as the interim Principal Accounting Officer of Skye Bioscience, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655121000015/0001516551-21-000015-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"602188ceb5","claim":"Kaitlyn Arsenault was appointed as Chief Financial Officer at Skye Bioscience, Inc..","evidence_excerpt":"On October 4, 2021, the Board of Directors of the Company (the “Board”) appointed Kaitlyn Arsenault as the new Chief Financial Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655121000015/0001516551-21-000015-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}